Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 7681 results

  1. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  2. Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway

    In development [GID-HTE10047] Expected publication date: 19 December 2024

    Health technology evaluations
    In development

  3. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 December 2024

    Technology appraisal guidance
    In development

  6. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  8. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  9. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

    In development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  10. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

    In development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  11. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development